Avraham Pharmaceuticals Ltd.
Tel Aviv
8 articles about Avraham Pharmaceuticals Ltd.
-
Avraham Pharmaceuticals Ltd. Closes An Additional Investment Round Of Approximately $4.0 Million
2/25/2016
-
Avraham Pharmaceuticals Ltd. Announces Successful Second Interim Results In Phase IIb Study Of Ladostigil For The Treatment Of Mild Cognitive Impairment
7/28/2015
-
Avraham Pharmaceuticals Ltd. Raises $4.5 Million In Additional Investment Led By Yissum
9/17/2014
-
Avraham Pharmaceuticals Ltd. Announces Successful Interim Results In Phase 2b Study Of Ladostigil For The Treatment Of MCI
7/8/2014
-
Avraham Pharmaceuticals Ltd. Closes a $6 Million Investment
2/21/2013
-
Avraham Pharmaceuticals Ltd. Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI
5/17/2012
-
Avraham Pharmaceuticals Ltd. Receives Orphan Medicinal Product Designation for Tivozanib for the Treatment of Renal Cell Carcinoma by the European Medicines Evaluation Agency
6/24/2010
-
Yissum Ltd., Pontifax, and Clal Biotechnology Industries Invest $9 Million in Avraham Pharmaceuticals Ltd. to Pursue a Phase IIb Clinical Trial of Ladostigil, a Novel Drug for Treatment of Alzheimer's Disease
4/14/2010